- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 58 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- /C O R R E C T I O N -- CytoSorbents Corporation/
- CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding
- CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
- CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials
- CytoSorbents Announces Virtual Annual Meeting
- CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
- CytoSorbents Reports First Quarter 2020 Financial and Operational Results
- slider1.jpg
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world